Kenneth T. Bogen
Research Subjects
Kenneth T. Bogen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Andrew Taylor
Trace Elements Centre, Royal Surrey County Hospital, Guildford, United Kingdom
1 shared publicationJ Daniels
1 shared publication- Joyce S. Tsuji
Exponent, Inc., Bellevue, WA, USA
1 shared publication L C Hall
1 shared publication- Marina Patriarca
Rome, Italy
1 shared publication - Michael D. Taylor
NiPERA, Inc, Durham, NC, USA
1 shared publication
Latest Publications
- 23 March 2023
- Published by Elsevier in Environmental Research
- Vol. 230, 115047
Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model
- 23 March 2023
- Published by Elsevier in Environmental Research
- Vol. 230, 115047
Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model
- Open Access
- 21 July 2021
- Published by Taylor & Francis in Human and Ecological Risk Assessment: An International Journal
- Vol. 27 (8) , 2015-2037
Human biokinetic model for soluble nickel addressing inter-individual variation
Worker-specific Biological Exposure Action Levels (BEALs) for nickel (Ni) exposure are a urinary Ni concentration that reflects a dose that can be experienced on a daily basis without adverse systemic health effects. Several health-based reference values for systemic exposure to Ni have been derived as oral daily Ni dosing levels (e.g., 2007 WHO tolerable daily intake for Ni). To support evaluation of urinary nickel biomonitoring data in workers based on such health-based criteria, new human biokinetic models for nickel (Ni) were fit jointly to data obtained for 18 adult volunteers from four newly reported human studies and to data from two previously reported studies involving a total of 14 adult volunteers. This model and associated statistical analyses characterize and predict human Ni biokinetics after ingestion of Ni doses ≤ 20 µg/kg bw and associated inter-individual variation in urinary Ni excretion. Using this approach, we illustrate how available health-based reference values for daily Ni exposure by the oral route developed to protect against adverse health effects can be applied to derive urinary nickel BEALs for nickel workers based on their individual characteristics (e.g., shift pattern, body weight). Such worker-specific BEALs can provide health-based reference values to evaluate measures obtained through urinary Ni biomonitoring programs to complement existing industrial hygiene air monitoring programs.
- 21 July 2021
- Published by Taylor & Francis in Human and Ecological Risk Assessment: An International Journal
- Vol. 27 (8) , 2015-2037
Open AccessHuman biokinetic model for soluble nickel addressing inter-individual variation
Worker-specific Biological Exposure Action Levels (BEALs) for nickel (Ni) exposure are a urinary Ni concentration that reflects a dose that can be experienced on a daily basis without adverse systemic health effects. Several health-based reference values for systemic exposure to Ni have been derived as oral daily Ni dosing levels (e.g., 2007 WHO tolerable daily intake for Ni). To support evaluation of urinary nickel biomonitoring data in workers based on such health-based criteria, new human biokinetic models for nickel (Ni) were fit jointly to data obtained for 18 adult volunteers from four newly reported human studies and to data from two previously reported studies involving a total of 14 adult volunteers. This model and associated statistical analyses characterize and predict human Ni biokinetics after ingestion of Ni doses ≤ 20 µg/kg bw and associated inter-individual variation in urinary Ni excretion. Using this approach, we illustrate how available health-based reference values for daily Ni exposure by the oral route developed to protect against adverse health effects can be applied to derive urinary nickel BEALs for nickel workers based on their individual characteristics (e.g., shift pattern, body weight). Such worker-specific BEALs can provide health-based reference values to evaluate measures obtained through urinary Ni biomonitoring programs to complement existing industrial hygiene air monitoring programs.
- Open Access
- 1 April 2019
- Published by SAGE Publications in Dose-Response
- Vol. 17 (2)
Inflammation as a Cancer Co-Initiator: New Mechanistic Model Predicts Low/Negligible Risk at Noninflammatory Carcinogen Doses
Linear-no-threshold (LNT) risk extrapolation has long been applied to estimate risks posed by low-level environmental carcinogen exposures, based on the 60-year-old multistage somatic mutation/clonal expansion (MSM) cancer theory. Recent evidence supports an alternative theory: Malignant tumors arise most efficiently from a stem cell that incurs requisite mutations and also is activated by inflammation to an epigenetically mediated and maintained state of adaptive hyperplasia (AH). This new inflammation-MSM (ISM) theory posits that inflammation-activated stem cells normally restricted to sites of injury-induced inflammation and tissue repair become uniquely susceptible to efficient carcinogenesis if normal post-inflammation AH termination is blocked by mutation. This theory posits that inflammation generally thus co-initiates cancer and transiently amplifies activated stem cells, implying that MSM theory (eg, the 2-stage stochastic “Moolgavkar, Venzon, Knudson [MVK]” model) is incomplete. Because inflammation dose–response typically is not LNT, the ISM theory predicts this is also true for most (perhaps all) carcinogens. The ISM (but not the MVK) model is shown to be consistent with recent data showing ∼100% carcinoma incidence (but not DNA adducts) in livers of rats exposed to aflatoxin B1 and was eliminated when that dose was co-administered with a highly potent anti-inflammatory agent. Experimental approaches to test ISM theory more robustly are discussed.
- 1 April 2019
- Published by SAGE Publications in Dose-Response
- Vol. 17 (2)
Open AccessInflammation as a Cancer Co-Initiator: New Mechanistic Model Predicts Low/Negligible Risk at Noninflammatory Carcinogen Doses
Linear-no-threshold (LNT) risk extrapolation has long been applied to estimate risks posed by low-level environmental carcinogen exposures, based on the 60-year-old multistage somatic mutation/clonal expansion (MSM) cancer theory. Recent evidence supports an alternative theory: Malignant tumors arise most efficiently from a stem cell that incurs requisite mutations and also is activated by inflammation to an epigenetically mediated and maintained state of adaptive hyperplasia (AH). This new inflammation-MSM (ISM) theory posits that inflammation-activated stem cells normally restricted to sites of injury-induced inflammation and tissue repair become uniquely susceptible to efficient carcinogenesis if normal post-inflammation AH termination is blocked by mutation. This theory posits that inflammation generally thus co-initiates cancer and transiently amplifies activated stem cells, implying that MSM theory (eg, the 2-stage stochastic “Moolgavkar, Venzon, Knudson [MVK]” model) is incomplete. Because inflammation dose–response typically is not LNT, the ISM theory predicts this is also true for most (perhaps all) carcinogens. The ISM (but not the MVK) model is shown to be consistent with recent data showing ∼100% carcinoma incidence (but not DNA adducts) in livers of rats exposed to aflatoxin B1 and was eliminated when that dose was co-administered with a highly potent anti-inflammatory agent. Experimental approaches to test ISM theory more robustly are discussed.
- Open Access
- 1 September 1999
- Published by Office of Scientific and Technical Information (OSTI)
Procedures for addressing uncertainty and variability in exposure to characterize potential health risk from trichloroethylene contaminated groundwater at Beale Air Force Base in California
This study was designed to accomplish two objectives. The first was to provide to the US Air Force and the regulatory community quantitative procedures that they might want to consider using for addressing uncertainty and variability in exposure to better characterize potential health risk. Such methods could be used at sites where populations may now or in the future be faced with using groundwater contaminated with low concentrations of the chemical trichloroethylene (TCE). The second was to illustrate and explain the application of these procedures with respect to available data for TCE in ground water beneath an inactive landfill site that is undergoing remediation at Beale Air Force Base in California. The results from this illustration provide more detail than the more traditional conservative deterministic, screening-level calculations of risk, also computed for purposes of comparison. Application of the procedures described in this report can lead to more reasonable and equitable risk-acceptability criteria for potentially exposed populations at specific sites.
- 1 September 1999
- Published by Office of Scientific and Technical Information (OSTI)
Open AccessProcedures for addressing uncertainty and variability in exposure to characterize potential health risk from trichloroethylene contaminated groundwater at Beale Air Force Base in California
This study was designed to accomplish two objectives. The first was to provide to the US Air Force and the regulatory community quantitative procedures that they might want to consider using for addressing uncertainty and variability in exposure to better characterize potential health risk. Such methods could be used at sites where populations may now or in the future be faced with using groundwater contaminated with low concentrations of the chemical trichloroethylene (TCE). The second was to illustrate and explain the application of these procedures with respect to available data for TCE in ground water beneath an inactive landfill site that is undergoing remediation at Beale Air Force Base in California. The results from this illustration provide more detail than the more traditional conservative deterministic, screening-level calculations of risk, also computed for purposes of comparison. Application of the procedures described in this report can lead to more reasonable and equitable risk-acceptability criteria for potentially exposed populations at specific sites.
- 1 January 1995
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 25 (1) , 37-49
Improved prediction of carcinogenic potencies from mutagenic potencies for chemicals positive in rodents and the ames test
Most studies of correlation between logs of mutagenic potency (MP) and cancer potency (CP) have obtained relatively small but statistically significant estimates of correlation (r) and corresponding log‐log slope (b, in Log[CP] = a + b Log[)MP]). But for mutagenic carcinogens, multistage cancer theory predicts that b and r should be highest when MP values best estimate mutation yields per unit dose at concentrations at least as high as those observed to cause cancer in bioassay animals. To test this hypothesis, the correlation of Ames test and rodent cancer potencies was examined for a total number n of 134 chemicals reported as positive in both assays. Values of maximum significant cancer potency (CP, in [mmol/kg‐day]−1) were obtained from a published carcinogenic potency database. Values of maximum mutagenic potency (MP, as revertants per mmol/L‐plate) were estimated from 2,347 sets of Ames test data reported by the NTP mutagenicity testing program, supplemented by similar data newly obtained for ten heterocyclic amines. For compounds with one or more significantly positive MP estimates based on approximately linear Ames test dose‐response data, linear regression of maximum values of Log(CP) on Log(MP) yielded b = 0.27 ± 0.065 and r = 0.39 (P = 0.0001, n = 105), similar to previously reported results for relatively large n. As predicted, when MP values were additionally restricted to include only values estimated from Ames test data approximately linear at corresponding lowest‐TD50 concentrations, similar regressions yielded significantly improved fits (e.g,. b and r = 0.6, P < 10−7, n = 68). Implications of these findings are discussed concerning the quantitative role that mutations like those measured in the Ames test may have in explaining observed cancerbioassay results.
- 1 January 1995
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 25 (1) , 37-49
Improved prediction of carcinogenic potencies from mutagenic potencies for chemicals positive in rodents and the ames test
Most studies of correlation between logs of mutagenic potency (MP) and cancer potency (CP) have obtained relatively small but statistically significant estimates of correlation (r) and corresponding log‐log slope (b, in Log[CP] = a + b Log[)MP]). But for mutagenic carcinogens, multistage cancer theory predicts that b and r should be highest when MP values best estimate mutation yields per unit dose at concentrations at least as high as those observed to cause cancer in bioassay animals. To test this hypothesis, the correlation of Ames test and rodent cancer potencies was examined for a total number n of 134 chemicals reported as positive in both assays. Values of maximum significant cancer potency (CP, in [mmol/kg‐day]−1) were obtained from a published carcinogenic potency database. Values of maximum mutagenic potency (MP, as revertants per mmol/L‐plate) were estimated from 2,347 sets of Ames test data reported by the NTP mutagenicity testing program, supplemented by similar data newly obtained for ten heterocyclic amines. For compounds with one or more significantly positive MP estimates based on approximately linear Ames test dose‐response data, linear regression of maximum values of Log(CP) on Log(MP) yielded b = 0.27 ± 0.065 and r = 0.39 (P = 0.0001, n = 105), similar to previously reported results for relatively large n. As predicted, when MP values were additionally restricted to include only values estimated from Ames test data approximately linear at corresponding lowest‐TD50 concentrations, similar regressions yielded significantly improved fits (e.g,. b and r = 0.6, P < 10−7, n = 68). Implications of these findings are discussed concerning the quantitative role that mutations like those measured in the Ames test may have in explaining observed cancerbioassay results.